SanaCurrents on Precision Bio’s (DTIL) second-generation ‘stealth” CAR T cell therapy in cancer
Precision Biosciences, Inc. (NASDAQ:DTIL) Probability Sentiment SUMMARY While a handful of autologous CAR T cell [...]
We Are Paying Attention To This Nearly 100 Year Old Customer Experience Company [GeoWire Weekly No. 68]
This January, our first Fireside Chat was with a nearly 100 yr-old company that takes a multi-channeled, technology enabled, approach to customer experience (CX), operating through three segments: Marketing Services, Customer Care, and Fulfillment & Logistics Services. It's not our first talk with a company involved in a part of that industry, who dealt with customer satisfaction and employee standard operating protocol management, which could be viewed as a subset of CX. We argued that in the post-Covid era there would be an increased need to put an emphasis on the way businesses understand their customers, and why it’s now more important than ever. As the world sees it, there is plenty of room for CX to grow. A study conducted by Grand View Research determined that...
SanaCurrents on Aadi Bio’s (AADI) expansion of nab-Sirolimus to solid tumor cancers
Aadi Bioscience, Inc. (NASDAQ:AADI) Probability Sentiment SUMMARY Shortly after listing in mid-2021, Aadi Bioscience, Inc. [...]
How Investors Can Turn a Profit from Stocks Going Through Bankruptcy [GeoWire Weekly No. 67]
In light of the riskier market environment we are in, I have been writing to you about our new Recession Proof and Recession Resistant Model Portfolios. A great related next step is to dive deeper into the tunnel and focus on the topic of Chapter 11 Bankruptcy and how to profit by focusing on two buckets: 1) Companies that survive a bankruptcy process. Will Muscle Pharm Corp (OTC:MSLPQ) be a candidate? 2) Companies whose businesses will actually benefit as bankruptcies increase, such as Heritage Global Inc. (NASDAQ:HGBL) and Creditriskmonitor.com Inc (OTC:CRMZ)
SanaCurrents on Syndax’s (SNDX) rising drug to treat rare, acute leukemias
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Probability Sentiment SUMMARY Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is advancing the small [...]
GeoWire Monthly, Vol. 3, Issue No. 1, January 2023
We’ll be getting back to the normal Monthly GeoWire format next month, but we wanted to take this first edition of the new year to look back at everything we were up to in 2022. Don’t worry, we will be getting back to our normal video format starting in February. This month’s GeoWire will be split up into 2 issues - one today, and the other next week. A lot happened in 2022, and we thought it was best to split it up into two separate posts to be able to put adequate focus on the themes we want to discuss. This Week: The stock market and recession, our new Model Recession Portfolios, and still the chance to participate in our special offer for 2023.
Non-GAAP – The Pragmatic Approach to Earnings Analysis [GeoWire Weekly No. 66]
In 2016 we addressed the dichotomous approach to understanding the differences between generally accepted accounting principles (GAAP) and non-GAAP earnings. There are ways they should be scrutinized when trying to get a sense if numbers being reported by a company are a true representation of what is going on at the net income level. Non-GAAP financials are also referred to as “adjusted.” For example, “adjusted earnings per share (EPS) or “adjusted earnings before interest taxes & depreciation & amortization (EBITDA). Because we plan on delving into this subject in a Tweet thread that we anticipate will engage our investor network and extensions thereof, we feel it is a good idea to give another primer on the subject, especially since GeoInvesting’s Premium Subscriber base has grown substantially since 2016. If part of your investment strategy is executing bullish or bearish short-term stock trades on earnings report news flow, it’s extremely important to understand if the GAAP and Non-GAAP earnings per share numbers being reported in a press release are “clean”.
SanaCurrents on X4 Pharma’s (XFOR) small molecule to treat chronic neutropenia
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Probability Sentiment SUMMARY X4 Pharmaceuticals, Inc.’s (NASDAQ:XFOR) mavorixafor posted impressive clinical [...]